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ARTICLE

Impact of SLCO1B1 Genetic Variation on Rosuvastatin
Systemic Exposure in Pediatric Hypercholesterolemia
Jonathan B. Wagner1,2,3,*, Susan Abdel-Rahman2,3, Andrea Gaedigk2,3, Roger Gaedigk2,3, Geetha Raghuveer1,3, Vincent S. Staggs3,4,
Leon Van Haandel2,3 and J. Steven Leeder2,3

This study investigated the impact of SLCO1B1 genotype on rosuvastatin systemic exposure in hypercholesterolemic children
and adolescents. Participants (8–21 years) with at least one allelic variant of SLCO1B1 c.521T>C (521TC, n = 13; 521CC, n = 2)
and wild type controls (521TT, n = 13) completed a single oral dose pharmacokinetic study. The variability contributed by
SLCO1B1 c.521 sequence variation to rosuvastatin (RVA) systemic exposure among our pediatric cohort was comparable
to previous studies in adults. RVA concentration-time curve from 0–24 hours (AUC0–24) was 1.4-fold and 2.2-fold higher in
participants with c.521TC and c.521CC genotype compared 521TT participants, respectively. Interindividual variability of
RVA exposure within SLCO1B1 genotype groups exceeded the ~ 1.5-fold to 2-fold difference in mean RVA exposure observed
among SLCO1B1 genotype groups, suggesting that other factors also contribute to interindividual variability in the rosuvastatin dose-exposure relationship. A multivariate model performed confirmed SLCO1B1 c.521T>C genotype as the primary
factor contributing to RVA systemic exposure in this pediatric cohort, accounting for ~ 30% of the variability RVA AUC0–24.
However, of the statins investigated to date in the pediatric population, RVA has the lowest magnitude of variability in systemic exposure.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
✔ In children with hypercholesterolemia, response to
3-hydroxy-3-methyl-glutaryl Coenzyme A reductase inhibitors (statins) is variable. In adults, genetic variation of
SLCO1B1 influences the pharmacokinetics of statins. To
date, the mechanisms that influence statin disposition in a
developing child is unknown.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ In the present study, we investigated the impact of
SLCO1B1 c.521C>T genotype on rosuvastatin (RVA) systemic exposure in children and adolescents.

Rosuvastatin (RVA) is a hydrophilic, synthetic inhibitor of
3-hydroxy-3-methyl-glutaryl Coenzyme A reductase, labeled to treat children 8 years and older with heterozygous
familial hypercholesterolemia.1–3 RVA is administered in
active acid form and undergoes hepatocellular uptake via
the drug transporters, OATP1B1, OATP1B3, OATP2B1, and
NTCP.1,4 Minor cytochrome P450 (CYP)-mediated metabolism via CYP2C9 leads to the formation of a minimally active
metabolite, N-desmethyl rosuvastatin (NDMRV; Figure 1).1,2
RVA undergoes phase II metabolism via UGT1A3 leading to

WHAT DOES THIS STUDY ADDS TO OUR KNOWLEDGE?
✔ Similar to adults, SLCO1B1 c.521 allelic variation impacts the pharmacokinetics of RVA in children, however,
other unknown factors contribute to interindividual variability in the dose-exposure relationship. There is less interindividual variability in RVA compared with pravastatin
and simvastatin in the pediatric population.
HOW MIGHT THIS CHANGE CLINICAL PHARMA
COLOGY OR TRANSLATIONAL SCIENCE?
✔ This study highlights that less variability in systemic
exposure was observed with children and adolescents
dosed RVA compared with pravastatin and simvastatin.

the formation of an inactive metabolite, rosuvastatin lactone
(RVL).5 RVA is also a substrate for BCRP, responsible for hepatic clearance into the bile.6,7 Due to its hydrophilic nature,
RVA, similar to pravastatin, may experience less passive
diffusion across the blood brain barrier8,9 and skeletal muscle,1,10–15 making it a potentially safer statin alternative for
maturing brains and myocytes in children compared with
highly lipophilic statin agents (e.g., simvastatin).
Two double-blind, randomized, placebo-controlled trials of
rosuvastatin in children (ages 6–17 years) have demonstrated
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Figure 1 Rosuvastatin (RVA) pathway. RVA undergoes CYP2C9-mediated biotransformation to N-desmethyl rosuvastatin and UGTmediated lactonization to form RVA lactone.

an ~ 35–50% reduction in low density lipoprotein cholesterol
(LDL-C), validating its efficacy in this age group.16,17 However,
considerable (approximately three- to fivefold) interindividual
variability in drug response, as indicated by reductions in
LDL-C, has been observed.18 Additionally, ~ 35–60% of participants failed to achieve the target LDL-C goal (< 130 mg/dL)
despite documented adherence to the drug.16,17 With this
large degree of variability in response and unknown long-term
effects of chronic statin exposure, providing dose-optimization (e.g., the lowest dose that achieves maximal response

with minimal risk of toxicity) is essential to improving hypercholesterolemia treatment in the developing child.
In order to investigate the etiology of interindividual variability in statin response, however, we must determine if
poor or no response is a function of inadequate drug exposure or altered drug target engagement due to diminished
expression and/or function of the drug target proteins.
One of the largest sources of variation in the dose-exposure
relationship is hepatic uptake of statins to the site of action within the liver. The SLCO1B1 gene encoding the
www.cts-journal.com
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hepatic drug transporter OATP1B1 has been shown to be
a major contributor to RVA transport.4 Furthermore, the
c.521T>C single nucleotide polymorphism (rs4149056)
located in exon 5 of the SLCO1B1 gene affects the localization of the transporter on the basolateral membrane of
the human hepatocyte.19 Functionally, this alteration leads
to a nonsynonymous amino acid change (Val174Ala) that
contributes to decreased human hepatocyte uptake4 and
increased RVA systemic exposure.20,21 In adults, Pasanen
et al.20 demonstrated that a SLCO1B1 single nucleotide
polymorphism (SNP; c.521T>C in exon 5) was associated
with an ~ 1.5-fold increase in RVA exposure compared
with participants with the reference genotype (c.521TT).
The association between SLCO1B1 c.521T>C gene variation and clinical response to statins (e.g., LDL-C reduction,
myopathy) has been demonstrated in several studies,22–25
but in large part, the association regarding its impact on
LDL-C reduction remains ambiguous.26–28 The largest association of SLCO1B1 gene variation and myopathy has
been observed with simvastatin acid and current Clinical
Pharmacogenetics Implementation Consortium (CPIC)
guidelines are available for simvastatin dosing according
to SLCO1B1 genotype.29
Growth and development may modulate the magnitude
of the genotype-phenotype relationship in children, limiting the extrapolation of adult data to hypercholesterolemic
children. In our recent pediatric genotype-stratified, singledose, pharmacokinetic study of simvastatin in children
> 8 years, the genotype-phenotype relationship observed in
adults was confirmed with each copy of the variant c.521C
allele contributing to a 2.5-fold increase in simvastatin acid
systemic exposure.30 The magnitude of the genotype effect was twofold greater in children compared with adults,
suggesting SLCO1B1 c.521T>C is more influential in children. In contrast, the magnitude of genotype effect in the
same cohort of children receiving pravastatin was comparable to adults.31,32 Of concern though, was the extent of
interindividual variability in simvastatin and pravastatin systemic exposure that was observed within genotype groups
(~ 8-fold to 17-fold range).31,33 Currently, the influence of
ontogeny on the RVA dose-exposure relationship is not
well-established.
Understanding the impact of ontogeny on the genotype-phenotype relationship for key drug transporters
influencing statin disposition is of critical importance in
optimal dose selection for pediatric patients. Thus, the
primary goal of this investigation was to establish the role
of genetic variation in SLCO1B1 on the rosuvastatin doseexposure relationship in hypercholesterolemic children and
adolescents.
METHODS
Subjects
Subjects meeting inclusion and exclusion criteria for this
study (Supplemental Materials S1) were recruited from the
Children’s Mercy Hospital Cardiology Pharmacogenomics
Repository, a living biorepository and patient registry designed to facilitate genotype-guided clinical trial participant
selection. Cardiology Pharmacogenomics Repository enrollees were invited to participate based on their SLCO1B1
Clinical and Translational Science

c.521T>C genotype status. Reference genotype (c.521TT)
and heterozygous variant populations (c.521TC and
c.521CC) were age-matched, ethnicity-matched, and
gender-matched. The study protocol was reviewed and approved by the Children’s Mercy Hospital Institutional Review
Board and the study conducted in accordance with US
and international standards of Good Clinical Practice (US
Food and Drug Administration (FDA) regulations 21 Code of
Federal Regulations (CFR) 312 for Investigational New Drug
studies and FDA guidance E6).
Genetic analysis
Genomic DNA was isolated from biospecimens using
Sigma GeneElute Mammalian Genomic DNA Miniprep Kit
(St. Louis, MO) or QIAamp DNA Blood Mini Kit (Valencia,
CA) according to manufacturer protocols. All DNA samples were genotyped for the common SLCO1B1 SNPs
−11187G>A (rs4149015), c.388A>G (rs2306283), and
c.521T>C (rs4149056) using TaqMan SNP genotyping assays (LifeTechnologies, Carlsbad, CA) with KAPA Probe
Fast qPCR Master Mix (2X) ABI Prism (KAPA Biosystems,
Boston, MA) on a QuantStudio 12 k Flex Real-Time PCR
System (Applied Biosystems, Foster City, CA). Five to
20 ng of DNA was used per reaction. The cycling conditions for all assays were as recommended by the
manufacturer. DNA samples from the Coriell Institute for
Medical Research were used as controls. Twenty percent
of samples were randomly selected and repeated for quality control. All reanalyzed samples were concordant with
the original results.
To identify sequence variations in SLCO1B1, SLCO1B3,
SLCO2B1, SLC10A1, ABCG2, CYP2C9, and UGT1A3
next-generation sequencing (NGS) was performed. Briefly,
a TruSeq Library was constructed according to manufacturer’s protocol (Illumina, San Diego, CA). A custom targeted
capture sequencing panel (Integrated DNA Technologies,
Coralville, IA) was used for enrichment. Samples were sequenced on an MiSeq instrument (Illumina) with paired end
200 base pair reads. Read coverage was ~ 500×. SLCO1B1
genotypes obtained by Taqman genotyping were 100%
consistent with the NGS data.
CYP2C9 and UGT1A3 genotype calls were made as following: CYP2C9 genotype was called using Astrolabe, a
bioinformatic tool that allows star allele calling from NGS
data.33,34 Astrolabe has been expanded to CYP2C9 and 2C19
(manuscript in preparation). For UGT1A3, an SNP report was
generated and star alleles manually called using definitions
per the UGT Nomenclature site at https://www.pharmacoge
nomics.pha.ulaval.ca/ugt-alleles-nomenclature/.
Study design
This was a single-center, open-label, genotype-stratified,
single oral dose pharmacokinetic study, comparing the
disposition of rosuvastatin among hypercholesterolemic
children and adolescents with one or more SLCO1B1
c.521C variant alleles to patients homozygous for the reference c.521TT genotype. Participants on current statin
therapy withheld statin administration for a washout period of 7 days prior to the drug study visit. All participants
had a screening physical examination (including Tanner
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Staging) performed by a licensed physician prior to drug
administration.
Subjects ingested a single oral dose of rosuvastatin
(ages 8–21 years: 10 mg tablet, Glenmark Pharmaceuticals,
Lot Number FC0259) with 150 mL of water after an overnight fast and resumed meals no earlier than 3 hours after
administration of the study dose. Serial venous blood
samples (1.5 mL each) were drawn from an indwelling venous cannula before pravastatin administration (time 0),
and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 7, 9, 18, and 24 hours
post-ingestion to measure plasma drug and metabolite
concentrations. Samples were collected in a syringe,
transferred to a tube containing potassium EDTA, gently
mixed by inversion, and immediately centrifuged at 4ºC for
10 minutes at 600 g. Plasma was removed and stored at
−80ºC until analysis. Predose urine and pooled postdose
urine were collected through the duration of the study
(24 hours).
Analytical methods
Plasma and urine concentrations of RVA, RVL, and NDMRV
were measured on a Waters TQ-S triple quadrupole tandem
mass spectrometer with a novel ultra-high pressure liquid
chromatography-tandem mass spectrometric method previously developed and validated in our laboratory.35 In brief,
the dynamic range of the assay was from 0.5–100 nM for
all analytes. The method was linear for all analytes in the
concentration range 0.5–100 nM with intraday and interday
precisions (as relative SD) of ≤ 10.3% and accuracy (as relative error) ranging from 97–111% at all quality control levels
(1, 10, and 75 nM). Plasma samples were analyzed in duplicate. For instances where the coefficient of variation in the
duplicates exceeded 20%, the samples were rerun (< 5%
of samples).
Pharmacokinetic parameters
Power calculations to determine sample size for our
study are detailed in Supplemental Materials S1.
Pharmacokinetic analyses were conducted using Kinetica
version 5.0 (ThermoFisher Scientific, Philadelphia, PA).
Plasma concentration vs. time data for RVA, RVL, and
NDMRV were curve fit using a peeling algorithm to generate initial monoexponential parameter estimates. Final
estimates of the terminal elimination rate constant (λ z)
were determined from an iterative, linear least squares
regression algorithm. A model-independent approach
was used and parameters of interest determined as follows. Individual peak plasma concentration (Cmax) and
time to maximal concentration (Tmax) were obtained
by direct examination of the plasma concentration vs.
time profile. The area under the plasma concentration
vs. time curve during the sampling period (AUC 0–n) was
calculated using the mixed log-linear method, where n
refers to the final sampling time with quantifiable drug
or metabolite concentrations. Extrapolation of the AUC
to infinity (AUC 0–∞) was not performed; secondary peaking occurred in a significant number of subjects within
the cohort and, therefore, insufficient data points to accurately capture the terminal elimination phase for RVA
were available.

Statistical analysis
Pharmacokinetic data for the study cohort were examined
using standard descriptive statistics in JMP version 14
(SAS, Marlow, UK). Pharmacokinetic parameters reflective
of systemic exposure (Cmax and AUC0–n) were log-transformed
using the natural logarithm. The significance limit accepted
for all statistical analyses was α = 0.05. SLCO1B1 genotype
(c.521TT vs. c.521TC/CC) was treated as an independent
variable. Pharmacokinetic parameters were compared between demographic and genotype groups, using Welch’s
t-test and Kruskal–Wallis test given the non-normality of the
dependent variables. For the pharmacokinetic parameters
related to SLCO1B1 genotype groups (Table 2), Kruskal–
Wallis test was utilized. For the pharmacokinetic parameters
related to demographics (Table S3), both Welch’s t-test and
Kruskal–Wallis test were utilized.
We used linear regression to examine associations between RVA AUCn and individual SNPs. For each SNP, we
fit one model where the SNP was the only predictor of RVA
AUCn, and a second model where sex, body mass index
(BMI) percentile, and Tanner stage were added as covariates. For comparison, we also fit a base model with only
sex, BMI percentile, and Tanner stage as predictors, allowing us to compute how much additional variability in RVA
AUCn could be accounted for by adding each SNP variable
to the base model. Tanner stage was computed as the average of the Pubic Hair Scale score and Breast Development/
External Genitalia Scale score. CYP2C9 genotype was used
to create two variables for use in modeling: number of *1
alleles (0, 1, or 2) and number of *2 alleles (0, 1, or 2). For
all other SNPs, the count of variant alleles (0, 1, or 2) was
computed for use in modeling.
Because administration of a fixed dose of RVA resulted
in an almost fourfold range of weight-based doses (0.07–
0.28 mg/kg), pharmacokinetic exposure parameters (e.g.,
Cmax and AUC) were normalized to dose for each individual
participant by dividing the exposure parameter value by actual mg/kg dose received then multiplied by the mean mg/kg
dose for the entire cohort (e.g., participant AUC (ng*hour/mL)/
participant dose (mg/kg) * cohort mean dose (mg/kg)).
RESULTS
Participant characteristics and adverse events
A total of 28 children and adolescents (15 male and 13
female participants) were enrolled in this investigation. The
demographic and genetic constitution of the participant
population is detailed in Table 1. Demographic parameters
were similar between SLCO1B1 c.521T>C variant-containing
genotypes and c.521TT controls. Of note, the weight-based
dose received was similar between the genotype groups
(Table 1). No adverse events were 
reported during the
study.
Drug disposition profiles
The drug disposition profiles of RVA, RVL, and NDMRV
(Figure 2a–c) were consistent with first-order absorption
and elimination. RVA, RVL, and NDMRV were detected in
all participants. Secondary peaking, suggestive of enterohepatic recirculation, was noted on the RVA profiles of
11 participants (39%) precluding accurate assessment
www.cts-journal.com
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Table 1 Characteristics of participants stratified by SLCO1B1 genotypes
SLCO1B1
521 TT
(n = 13)
a

SLCO1B1
521 TC
(n = 13)

SLCO1B1
521 CC
(n = 2)

P value
0.965

15.2 (± 3.0)

15.0 (± 2.8)

14.4 (± 4.3)

Weight, kga

86.0 (± 34.2)

87.0 (± 25.8)

61.8 (± 1.6)

0.314

Height, cma

164.2 (± 8.6)

165.6 (± 11.9)

157.5 (± 20.0)

0.659

BMI, kg/m2a

31.6 (± 11.8)

31.1 (± 6.7)

25.5 (± 5.8)

0.695
0.994

Age, years

Sexb
Female

6

6

1

Male

7

7

1

Ethnicityb
White, non-Hispanic

7

7

1

White, Hispanic

5

5

1

African American

1

1

0

0.951

Tanner breast/testicularb
Stage 1

0

0

0

Stage 2

2

2

1

Stage 3

0

1

0

Stage 4

4

0

0

Stage 5

7

10

1

0.165

Pubicb
Stage 1

1

0

0

Stage 2

0

3

1

Stage 3

1

0

0

Stage 4

3

0

0

Stage 5
Dose, mg/kga

8

10

1

0.14 (± 0.06)

0.13 (± 0.04)

0.16 (± 0.00)

0.235

0.402

BMI, body mass index.
All data expressed as mean (± SD).
a
Designates Kruskal–Wallis test. bDesignates Chi-square test performed.

of the mean terminal elimination rate constant across the
population.
Overall, a relatively large degree of variability (approximately eightfold) was observed across the entire population
with respect to measures of systemic exposure for RVA
(median interquartile range (IQR), Cmax: 5.4 ng/mL (IQR
3.4–7.3 ng/mL); and AUC0–24: 42.7 ng*hour/mL (IQR 31.1–
60.3; Table S1). Significant variability was also observed for
RVL (median IQR, Cmax: 1.1 ng/mL (IQR 0.4–1.5); AUC0–24:
12.9 ng*hour/mL (IQR 7.3–21.5; Table S1) and NDMRV (median IQR Cmax: 0.8 ng/mL (IQR 0.5–1.1 ng/mL); AUC0–24:
4.7 ng*hour/mL (IQR 3.0–6.3); Table S1).
Effect of SLCO1B1 genotype on systemic exposure
Maximum mean RVA concentrations (Cmax) were 2.3-fold
higher in the c.521CC (n = 2) group and 1.4-fold higher in
the c.521TC (n = 13) group relative to the c.521TT (n = 13)
group (Figure 3a, Table 2). Mean RVA AUC0–24 was 2.2fold higher in the c.521CC group and 1.4-fold higher in the
c.521TC group relative to subjects with reference genotype
(Figure 3b, Table 2).
RVL exposure was similar among the SLCO1B1
genotype groups (P = 0.17; Table 2). Similarly, NDMRV exposure was similar among c.521TC and c.521CC groups
compared with c.521TT (reference) participants (P = 0.44;
Table 2).
Clinical and Translational Science

There was no relationship between RVA or related isomers
and the presence of SLCO1B1 −11187G>A (rs4149015) or
c.388A>G (rs2306283).
In addition to differences in RVA exposure among SLCO1B1
c.521 genotype groups, variability within genotype groups
was observed. The largest range of variability occurred in
the c.521TT group (5.5-fold) compared with the c.521TC
group (2.2-fold). Overall, these data indicate that additional
patient-specific variables, in conjunction with SLCO1B1 genotype, influence RVA systemic exposure. RVA exposure was not
normally distributed within the entire cohort or even within the
c.521TT and TC genotype groups. In fact, there were four participants within each group that deviated from normality in the
normal quantile plot (Figure S1) and, subsequently, these were
identified as a potential subgroup classified as “high outliers.”
Secondary post hoc analyses were conducted to seek
insight into additional factors contributing to high systemic
RVA exposure within SLCO1B1 genotype groups.
Effect of demographic and developmental factors on
systemic exposure
Simple linear regression analyses of RVA, RVL, NDMRV
AUC0–24 on independent variables (age, height, lean body
weight, and BMI) revealed only a few weak, positive correlations (Table S2). RVA and RVL AUC0–24 were similar among
sex and ethnicities (Table S3).
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Figure 2 Rosuvastatin (RVA) and related metabolite pharmacokinetic profiles (a) mean ± SD plasma concentrations (nM) of RVA
and dose-normalized RVA and (b) RVA lactone and dose-normalized rosuvastatin lactone (c) N-Desmethyl rosuvastatin and dosenormalized N-Desmethyl RVA after a single dose of RVA in 28 healthy pediatric participants. Black, gray, and open white circles
represent participants with the c.521TT (n = 13), c.521TC (n = 13), and c.521CC (n = 2) genotypes, respectively.

Effect of non-SLCO1B1 sources of genetic variation
on systemic exposure
Additional gene sequencing of hepatic transporters associated with RVA uptake (SLCO1B1, SLCO1B3, SLCO2B1,

and SLC10A1) and efflux (ABCG2) was performed on all
participants (Table S4). Gene sequencing of SLCO1B1
and SLCO2B1 revealed no additional sequence variations
implicating altered OATP1B1 or OATP2B1 expression
www.cts-journal.com
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Figure 3 Rosuvastatin (RVA) exposure (a) comparison of RVA peak plasma concentration (Cmax; ng/mL; P = 0.01) and (b) area under
the curve from 0 to 24 hours (AUC0→24; ng*hr/mL) normalized for dose among SLCO1B1 c.521 genotypes (P = 0.01). Black, gray, and
open white circles represent participants with the c.521TT (n = 13), c.521TC (n = 13), and c.521CC (n = 2) genotypes, respectively. Red
circles represent potential “high outlier” participants (c.521TT, n = 4; c.521TC, n = 4).
Table 2 Dose-normalized pharmacokinetic variables of RVA and
related analytes after a single dose of RVA in relationship to
SLCO1B1 genotype
SLCO1B1
c.521TT
(n = 13)

SLCO1B1
c.521TC
(n = 13)

SLCO1B1
c.521CC
(n = 2)

P
value

0.01

RVA
4.3 (± 2.3)

6.2 (± 2.2)

10.1 (± 0.6)

Tmax, hour

Cmax, ng/mL

5.0 (4.0–5.0)

4.0 (1.0–5.0)

4.0 (3.0–7.0)

N/A

AUC0–24,
ng/mL*hour

36.0 (± 18.5)

49.2 (± 14.0)

79.7 (± 18.2)

0.01

0.09

RVA lactone
Cmax, ng/mL
Tmax, hour
AUC0–24,
ng/mL*hour

0.8 (± 0.5)

1.2 (± 0.7)

1.4 (± 0.4)

5.0 (1.0–9.0)

4.5 (2.5–7.0)

5.0 (1.0–9.0)

N/A

11.8 (± 8.6)

17.2 (± 10.2)

18.5 (± 2.0)

0.17

0.50

N-Desmethyl RVA
Cmax, ng/mL
Tmax, hour
AUC0–24,
ng/mL*hour

0.8 (± 0.5)

1.0 (± 0.5)

1.0 (± 0.0)

4.0 (2.5–7.0)

4.0 (2.0–7.0)

5.0 (3.0–7.0)

N/A

5.4 (± 5.5)

5.8 (± 3.4)

5.7 (± 0.9)

0.44

AUC0–24, area under the curve from 0 to 24 hours; Cmax, peak plasma concentration; N/A, not applicable; RVA, rosuvastan; Tmax, time to maximal
concentration.
Data expressed as mean (± SD), Tmax expressed as median (range). Kruskal–
Wallis test utilized for all statistical analysis.

and/or function. There were seven participants with the
SLCO1B1 c.463C>A (rs11045819) known to result in increased OATP1B1 expression and function. However, two
“high outliers” had the rs11045819 variant (one c.521TT
and one c.521TC) and the other five participants (three
c.521TT and two c.521TC) were in the lower half of their
Clinical and Translational Science

respective genotype. Thus, rs11045819 variation alone
does not explain the dichotomy of the cohort within
SLCO1B1 c.521T>C genotype groups. Eight participants
had a nonsynonymous sequence variation in SLCO1B3
(c.767G>C; rs60140950) that alters transporter expression. The c.767G>C was detected in two “high outliers” in
the c.521TC group and one subject in the c.521TT group.
There was one additional “high outlier” in the c.521TC
group with a nonsynonymous sequence variation in
SLC10A1 (c.957G>A; rs149272163). In the entire cohort,
three c.521TT participants had a sequence variation in
ABCG2 (c.421C>A) with two of these participants being
“high outliers.” Six participants had a sequence variation in ABCG2 (c.34G>A) including one c.521TC and one
c.521TT “high outlier.” There were no participants having
both SNPs, ABCG2 c.34G>A and c.421C>A. Comparison
of each of these variants to wild type participants among
the entire cohort and within SLCO1B1 c.521T>C subgroups did not achieve significance. Although these
aforementioned sequence variations may potentially explain higher RVA exposure for six of the eight outliers,
none were solely unique to the “high outlier” group.
Effect of CYP2C9 and UGT on systemic exposure
To determine if altered CYP-mediated metabolism contributed to the extreme phenotype results within genotype
groups, differences in NDMRV metabolite formation
was assessed using postdose, pooled urine samples.
However, the recovery of NDMRV as a percentage of
the total analyte (RVA + RVL + NDMRV) in the aforementioned “high outliers” of both genotype groups was not as
a whole lower compared with others. Of note, three “high
outliers,” one c.521TC and two c.521TT participants,
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were within the normal quantile distribution plot (Figure
S2) with only one “high outlier” c.521TT participant in
the lower group having SNPs associated with one nonfunctional CYP2C9 allele (*1/*3). Collectively, CYP2C9
genotype may have contributed to higher RVA systemic
exposure for only one “high outlier,” but does not independently contribute to the variability within SLCO1B1
c.521T>C genotype groups.
Similarly, to determine if diminished lactonization in
the “high outliers” led to increased RVA systemic exposure, plasma RVL as a percentage of the total analyte
(RVA + RVL + NDMRV) was quantitated. However, the percentage RVL/total in the aforementioned “high outliers” of
both genotype groups was not as a whole lower compared
with others (Figure S3). Of note, two “high outliers,” one
c.521TC and one c.521TT participant within the lower end of
the normal quantile distribution plot, were present and none
of them had a sequence variation suggestive of diminished
UGT1A3 function. Collectively, UGT1A3 genotype does
not seem to contribute to the variability within SLCO1B1
c.521T>C genotype groups.
RVA multivariate model
We explored a number of multiple regression models
(e.g., models for SLCO1B1 genotypes and demographic
parameters), including multivariate models to quantify associations between the aforementioned SNPs and RVA
AUC0–24, controlling for BMI percentile, sex, and Tanner
Staging. The most significant SNP associated with RVA
AUC0–24 outcome was SLCO1B1 c.521T>C genotype,
yielding an R-squared value of 0.39 in the multivariate
model, as compared with an R-squared of 0.10 when only
the 3 covariates were included (Table S5). Collectively,
SLCO1B1 genotype seems to be the primary factor
contributing to RVA systemic exposure among those evaluated in our analysis.
DISCUSSION
The present study investigated the impact of SLCO1B1
genetic variation and developmental factors on RVA pharmacokinetics in children and adolescents. The magnitude
of effect for the c.521TC group compared with the reference genotype in children was similar to that reported in
adults (i.e., 1.4-fold in the current study vs. 1.6-fold as observed by Pasanen et al. 20. In contrast to the adult study
where only a difference was observed between reference
genotype and c.521CC, we observed a difference among
each genotype group. We do recognize that our conclusion with regard to c.521CC genotype is limited given the
small sample size (n = 2), this observation is, however, concordant with our previous simvastatin acid and pravastatin
acid analyses.31,33 In these studies, systemic exposure increased with each variant “C” allele that was present.31,33
The magnitude of the SLCO1B1 genotype effect for RVA
is less compared with that found for SVA but similar to
PVA in this pediatric cohort.31,33 Collectively, SLCO1B1
c.521T>C explained nearly three times more variability in
RVA exposure compared with BMI percentile, sex, and
Tanner Staging in our multivariate model.

Particularly striking was the observation of an ~ 5.5fold and 2.2-fold range of RVA systemic exposures within
the c.521TT and TC genotype groups, respectively (TT:
11.7–64.2 ng*hour/mL; TC: 35.3–78.9 11.7–64.2 ng*hour/mL;
Figure 3b). A similar observation has been described in
adults with coefficients of variation for RVA AUC ranging
from 36–51% within SLCO1B1 genotype groups.20,21 An
unexpected observation was the putative existence of two
separate groups within each SLCO1B1 c.521T>C genotype
group, as shown in Figure 3b and Figure S1. Eight of 28 participants (~ 30%) were deemed as “high outliers.” Collectively,
these data indicate that additional patient-specific variables,
in conjunction with SLCO1B1 genotype, influence RVA exposure and these need to be identified in order to effectively
tailor RVA treatment to the individual patient.
Our previous investigation involving pravastatin observed
that “high outliers” in the c.521TT group had the highest BMI
values (Z-score > +2.5) in the entire cohort, suggesting that
liver adiposity may compromise statin transport.31 Previous
investigations demonstrate a link between nonalcoholic
fatty liver disease and diminished hepatic uptake transporter
expression,36–38 subsequently altering simvastatin and
pravastatin transport.38,39 This association of obesity and diminished RVA transport (e.g., larger systemic exposure) was
not observed in this similar pediatric cohort. However, we
acknowledge that our studies were not specifically powered
to answer this particular post hoc analysis. Collectively, the
role of liver adiposity on pediatric statin disposition requires
further elucidation.
RVA is a known substrate of several other transporters, including OATP1B1, OATP1B3, OATP2B1, NTCP, and
ABCG21,4 and, thus, additional gene sequencing was performed to ascertain if other sequence variants existed in
the “high outliers” to explain the discordant results in our
study population (Table S4). There were seven participants that harbored the SLCO1B1 c.463C>A (rs11045819)
SNP associated with enhanced expression and function.
As shown in Table S4, two of our “high outliers” had
rs11045819 and five in the “lower” group had the SNP.
Thus, rs11045819 did not explain the dichotomy within
c.521T>C groups.
Of the eight outliers, three were found to have nonsynonymous sequence variants in SLCO1B3 (c.767G>C;
rs60140950) with one having homozygosity of the variant
allele. This SNP was previously investigated by Schwarz et
al.40 and was found to cause diminished total protein and
cell surface expression of OATP1B3, but was not implicated to result in diminished uptake of cholecystokinin-8,
a specific OATP1B3 substrate. Of note, they observed
other sequence variants that were associated with diminished cholecystokinin-8 and RVA uptake, but these were
not found in our “high outliers.” The role of SLCO1B3
c.767G>C on RVA uptake was not investigated as a part
of the aforementioned study but should be investigated in
future analyses.
One additional participant in the “high outlier” group had
a nonsynonymous SLC10A1 c.957G>A SNP. Previously,
Ho et al. reported discordant results with the NTCP*2
allele (SLC10A1 c.800C>T), despite known to result in
complete loss of function, having enhanced RVA uptake
www.cts-journal.com
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and NTCP*3 (SLC10A1 c.668T>C), known to alter cell
surface trafficking, having diminished RVA uptake. The
SLC10A1 c.957G>A SNP was not investigated as a part
of this study, but its effect on RVA should be validated in
future investigations.
ABCG2 (BCRP) is expressed on the apical membranes of
a variety of tissues, including the liver and small intestine,41
and decreased activity of ABCG2 secondary to the c.34G>A
and c.421C>A SNPs at the small intestine leads to enhanced
absorption. This resultant increase in bioavailability leads to
increased RVA systemic exposure, which has been confirmed in adult cohorts.42–44 Two of the six participants with
the ABCG2 c.34G>A SNP and two of three with the ABCG2
c.421C>A SNP were “high outliers.” Although this could
lead to the higher exposure within each genotype group for
some participants, these SNPs were not unique to the “high
outliers” (i.e., were also found in 5 other participants) and,
therefore, cannot be definitively concluded as the etiology
leading to RVA exposure above the 99% for the cohort.
The role of CYP2C9 genotype on RVA systemic exposure was evaluated in our study cohort, implying that if
RVA metabolism was impaired, it could result in higher
RVA systemic exposure. There was one “high outlier” with
an intermediate metabolizer CYP2C9 genotype. However,
this finding did not explain the clear separation of the
two groups within each SLCO1B1 genotype. Collectively,
CYP2C9 and UGT1A3 genotypes do not seem to have an
impact on the interindividual variability observed in the
rosuvastatin dose-exposure relationship in the pediatric
population.
LIMITATIONS OF STUDY
The primary goal of this investigation was to establish the
role of genetic variation in SLCO1B1 on the RVA doseexposure relationship in hypercholesterolemic children
and adolescents. Secondary post hoc analyses were conducted to ascertain if additional SNPs contributed to high
systemic RVA exposure within SLCO1B1 genotype groups.
We acknowledge that several of these tested SNPs had low
variant allele frequency and may not have been observed in
our cohort. In summary, we did observe some SNPs associated with altered RVA disposition, but no single sequence
variant consistently accounted for the presence of unexpectantly high RVA AUC.

of individuals within genotype groups compared with
pravastatin and simvastatin.31,33 Moving forward, RVA
may be the more ideal agent for future investigations that
develop clinical decision support tools to optimize outcomes for children prescribed a statin for the treatment
of hypercholesterolemia. Future analyses determining
the impact of less variable systemic exposure, as seen
with RVA, on the markers of short-term and long-term response, needs investigation prior to making it a preferred
agent in pediatric populations.
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CONCLUSION
Collectively, our study demonstrates that SLCO1B1 genotype contributed to the variability in the dose-exposure
relationship observed in the pediatric cohort, yet, within
each genotype group there exists variability that cannot
be explained by SLCO1B1 genotype alone. Alternative
proteins involved in RVA disposition may contribute to the
separation observed within the genotype groups, however, no single SNP tested consistently accounted for
the presence of expectantly high RVA AUC. Perhaps the
most insight comes from the finding that of the statins
investigated in the pediatric population, RVA had the
lowest magnitude of variability of systemic exposure
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